+
Site Tour
TRICLIP™
TRICUSPID
VALVE REPAIR
TRANSCATHETER
EDGE-TO-EDGE REPAIR (TEER)

 

Built upon a proven clip-based platform, TriClip™ Transcatheter Edge-to-Edge Repair (TEER) offers a minimally invasive treatment option for patients with symptomatic, severe Tricuspid Regurgitation (TR) who are at high risk for surgery.

THE FIRST CHOICE TO RESTORE THE TRICUSPID VALVE1

TriClip TEER has shown meaningful outcomes in both real-world and randomized clinical data. bRIGHT and TRILUMINATE™ Pivotal Trials demonstrated the safety and effectiveness of TriClip TEER in the treatment of severe Tricuspid Regurgitation (TR).2-6

IMPROVING QUALITY OF LIFE WITHOUT COMPROMISE2

The TRILUMINATE™ Pivotal Trial demonstrated that TriClip TEER therapy was superior to medical therapy alone in improving quality of life and reducing Tricuspid Regurgitation.

Remarkable and Sustained TR Reduction2

TR Grade (Core Lab)

Extremely Safe Profile at 30-days2

Freedom From
MAEs

New Pacemaker Implantation

Device Thrombus

Survival

Nonelective CV
Surgery from Device-Related AE

Device Embolization

Significant Improvement in Quality of Life and Functional Status at 30-days2
Baseline Population Characteristics2

71%

OF PATIENTS HAD MASSIVE
OR TORRENTIAL TR

4.4±0.7cm

TRICUSPID VALVE
ANNULUS DIAMETER

>35%

OF PATIENTS WITH PRIOR
VALVULAR INTERVENTION

15%

OF PATIENTS HAD A CRT, CRT-D, ICD,
OR PERMANENT PACEMAKER

TRILUMINATE PIVOTAL TRIAL DATA CARD

Get the latest data from the TRILUMINATE Pivotal Trial in a one-pager PDF format.
 

GET DATA CARD

PROVEN ACROSS A BROAD RANGE OF ANATOMIES7,8

The bRIGHT Study demonstrated that TriClip™ TEER significantly reduced TR across a broad range of anatomies - in a safe and effective procedure - resulting in durable and meaningful clinical outcomes.

Designed to Maximize TR Reduction7

TR Grade (Core Lab)

Successfully Treated a Broad Range of Anatomies8
Proven Durability Backed by Clinical Data7

NYHA Functional Class

KCCQ - OS

TriClip TEER demonstrated Procedural Success and a Strong Safety Profile5

HIGH PROCEDURAL
SUCCESS

Implant sucess rate

SHORT
DEVICE TIME


78±41

Minutes

HIGH SAFETY
PROFILE

Freedom from MAEs

99.7%
SURVIVAL

1.3%
REINTERVENTION

0%
EMBOLIZATION

bRIGHT STUDY DATA CARD

Get the latest data from the bRIGHT Study in a one-pager PDF format.
 

GET DATA CARD

PROVEN SAFETY AND EFFECTIVENESS

The TRILUMINATE™ Trial proved that TriClip TEER safely and effectively reduces TR and HF hospitalizations. 

93%

SURVIVAL
AT 1 YR3

100%

IMPLANT
SUCCESS4

91%

ACUTE PROCEDURAL
SUCCESS RATE4

0%

STROKE4

0%

CONVERSION TO
SURGERY4

Significant and Durable TR Reduction4

Durable reduction in tricuspid regurgitation (TR)

Significant improvement in function and quality of life3

Durable improvements in NYHA
 

20 Points significant improvement in KCCQ-OS health-related quality of life at one-year

TriClip TEER demonstrated a high safety profile4

HIGH SURVIVAL IN A FRAGILE
PATIENT POPULATION

Survival
at 1 year

LOW RATES OF MAJOR
ADVERSE EVENTS

Freedom from MAEs
at 1 year

Significant reduction in hospitalizations4

Reduced hospitalization rate
 

TRILUMINATE TRIAL DATA CARD

Get the latest data from the TRILUMINATE Trial in a one-pager PDF format.
 

GET DATA CARD

BRINGING YOU...

Clinical Case clubs | Educational tools | Hot topics
Expert opinions | Live & online discussions
 

TV

AV VALVES 2023: Fast Forward 20 Years

AV VALVES Summit 2023 Shaping the Future Part II: Fast Forward 20 Years

AV VALVES 2023: The Genesis of TEER

AV VALVES Summit 2023 Shaping the Future Part I: 20 years – The Genesis of TEER

AV VALVES 2023: TA, TF in TMVR

AV VALVES Summit 2023 Trending Controversies Round 3: TA, TF in TMVR

AV VALVES 2023: Replace, Repair in TR

AV VALVES Summit 2023 Trending Controversies Round 2: Replace, Repair in TR

AV VALVES 2023: Staged, Concomitant

AV VALVES Summit 2023 Trending Controversies Round 1: Staged, Concomitant 

AV VALVES 2023:Decision Making in HF–Tricuspid

AV VALVES Summit 2023 Decision Making in HF:How & when should I treat? Part II Tricuspid

AV VALVES 2023:Decision Making in HF – Mitral

AV VALVES Summit 2023 Decision Making in HF: How & when should I treat? Part I Mitral 

AV VALVES 2023:HF and VHD – Patient Management

AV VALVES Summit 2023 HF and VHD: Changing the Paradigm of Patient Management

AV VALVES 2023: Live Case – T-TEER

AV VALVES Summit 2023 Live Case: Tricuspid TEER

AV VALVES 2023: TR – Big Gaps

AV VALVES Summit 2023 Case Parade Tricuspid: Big Gaps

References
  1. Data on file at Abbott.
  2. Sorajja P, Whisenant B, Hamid N, et al. TRILUMINATE Pivotal: A Landmark Randomized Clinical Trial of Transcatheter Tricuspid Valve Edge-to-Edge Repair For Tricuspid Regurgitation.” Presented at ACC; March 4, 2023; New Orleans, LA; USA.
  3. von Bardeleben RS, Lurz P, Sitges M, et al. Percutaneous edge-to-edge repair for tricuspid regurgitation: 2-year outcomes from the TRILUMINATE trial. Presented at: EuroPCR 2021.
  4. Lurz P, von Bardeleben RS, Weber M, et al. Transcatheter edge-to-edge repair for treatment of tricuspid regurgitation. J Am Coll Cardiol. 2021;77(3):229-239.
  5. Lurz P, Lapp H, Schueler R, et al. Real-world outcomes for tricuspid edge-to-edge repair: initial 30-day results from the TriClip™ bRIGHT Study. Presented at: EuroPCR; May 17-20, 2022; Paris, France.
  6. Nickenig G., Weber M., Lurz P., et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. Lancet. 2019; 394 (10213): 2002-2011.
  7. Lurz P, Schmitz T, Bekeredjian R, et al. Real-world Outcomes for Tricuspid Edge-to-Edge Repair: Initial 1 Year Outcomes from the bRIGHT trial. Presented at PCR London Valves; November 27-29, 2022; London, England.
  8. Lurz P et al. Real-world Outcomes for Tricuspid Edge-to-Edge Repair: Initial 30-Day Results with TriClip™ G4 from the bRIGHT Study Presented at PCR London Valves 2022.

© Abbott 2023. All rights reserved. 9-EH-5-14380-01 07-2023

You are about to leave my-connext.com

You are now leaving my-connext.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

The content on this website is intended for healthcare professionals in EMEA with applicable health authority product registrations, excepted those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Click OK to confirm you are a healthcare professional to proceed.

OK Decline